✦ LIBER ✦

Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial

✍ Scribed by Hunsicker, Lawrence G.; Atkins, Robert C.; Lewis, Julia B.; Braden, Gregory; de Crespigny, Paul J. Champion; DeFerrari, Giacomo; Drury, Paul; Locatelli, Francesco; Wiegmann, Thomas B.; Lewis, Edmund J.

Book ID: 109066756
Publisher: Nature Publishing Group
Year: 2004
Tongue: English
Weight: 45 KB
Volume: 66
Category: Article
ISSN: 0085-2538
DOI: 10.1111/j.1523-1755.2004.09223.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Health economic implications of irbesart

Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis

✍ Andrew J. Palmer; William J. Valentine; Joshua A. Ray; Stephane Roze; Noemi Musz 📂 Article 📅 2007 🏛 Springer 🌐 French ⚖ 212 KB

The impact of glycaemic control on outco

The impact of glycaemic control on outcomes in patients with end-stage renal disease and type 2 diabetes (Review Article)

✍ SOPHIA ZOUNGAS; PETER G KERR; MICHELLE LUI; HELENA J TEEDE 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB

The impact of blood pressure measurement

The impact of blood pressure measurement methods on the assessment of differences in blood pressure levels between patients with normoalbuminuric type 1 diabetes and healthy controls

✍ Vervoort, G; Wetzels, J F M; Lutterman, J A; Berden, J H M; Thien, Th; Smits, P 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 101 KB

Effects of blood pressure lowering and i

Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial

✍ J. W. J. Beulens; A. Patel; J. R. Vingerling; J. K. Cruickshank; A. D. Hughes; A 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 186 KB

Weight and blood pressure response to we

Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial

✍ L. F. Van Gaal; I. D. Caterson; W. Coutinho; N. Finer; A. P. Maggioni; A. M. Sha 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 559 KB